Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257125 | 0.85 | CHRM2 (0.59) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3180231 | 0.83 | ALDH1A1 (0.44) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL11149580 | 0.79 | CHRM1 (0.50) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3292747 | 0.79 | CHRM1 (0.50) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13241378 | 0.79 | CHRM2 (0.37) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7809557 | 0.77 | — | — | |
| SCHEMBL937076 | 0.77 | CHRM2 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9618866 | 0.75 | CHRM1 (0.47) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8568039 | 0.75 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL30902061 | 0.74 | CHRM2 (0.50) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667511-A2 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250346553-A1 | Process for the Preparation of R-Oxybutynin Hydrochloride | HARMAN FINOCHEM LTD (IN) | 2025-11-13 | — | — | US | claimed |
| EP-4519242-A1 | PROCESS FOR THE PREPARATION OF R-OXYBUTYNIN HYDROCHLORIDE | Harman Finochem Limited (IN) | 2025-03-12 | — | — | EP | claimed |
| US-20240339358-A1 | METHOD OF FORMING A METAL LINER FOR INTERCONNECT STRUCTURES | APPLIED MATERIALS, INC. (US) | 2024-10-10 | — | — | US | claimed |
| WO-2024211169-A1 | METHOD OF FORMING A METAL LINER FOR INTERCONNECT STRUCTURES | APPLIED MATERIALS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| CN-116180076-B | Environment-friendly process applied to filling through holes of wafers | 深圳创智芯联科技股份有限公司 | 2024-07-26 | — | — | CN | claimed |
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4313170-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023214426-A1 | PROCESS FOR THE PREPARATION OF R-OXYBUTYNIN HYDROCHLORIDE | HARMAN FINOCHEM LIMITED (IN) | 2023-11-09 | — | — | WO | claimed |
| US-11724981-B2 | Cationic surfactants comprising an ether link | BATTELLE MEMORIAL INSTITUTE (US) | 2023-08-15 | — | — | US | claimed |
| US-20210139409-A1 | CATIONIC SURFACTANTS COMPRISING AN ETHER LINK | BATTELLE MEMORIAL INSTITUTE | 2021-05-13 | — | — | US | claimed |
| EP-3802727-A1 | CATIONIC SURFACTANTS COMPRISING AN ETHER LINK | Battelle Memorial Institute (US) | 2021-04-14 | — | — | EP | claimed |
| US-9505863-B2 | Process for the production of rubber ionomers and polymer nanocomposites | LANXESS INTERNATIONAL SA (CH) | 2016-11-29 | — | — | US | claimed |
| EP-2550303-B1 | PROCESS FOR THE PRODUCTION OF RUBBER IONOMERS AND POLYMER NANOCOMPOSITES | LANXESS INT SA (CH) | 2014-09-24 | — | — | EP | claimed |
| US-20130217833-A1 | PROCESS FOR THE PRODUCTION OF RUBBER IONOMERS AND POLYMER NANOCOMPOSITES | LANXESS INTERNATIONAL SA (CH) | 2013-08-22 | — | — | US | claimed |
| EP-2550303-A1 | PROCESS FOR THE PRODUCTION OF RUBBER IONOMERS AND POLYMER NANOCOMPOSITES | LANXESS International SA (CH) | 2013-01-30 | — | — | EP | claimed |
| WO-2011117277-A1 | PROCESS FOR THE PRODUCTION OF RUBBER IONOMERS AND POLYMER NANOCOMPOSITES | LANXESS INTERNATIONAL SA (CH) | 2011-09-29 | — | — | WO | claimed |
| US-4435254-A | ACETYLENIC AMINES AND SULFONATES | M&T CHEMICALS INC. (US) | 1984-03-06 | — | — | US | claimed |
| EP-0039787-B1 | PREPARATION PROCESS OF CYCLOPENTADIENE COPOLYMERS | BASF Aktiengesellschaft (DE) | 1983-07-06 | — | — | EP | claimed |
| US-4371676-A | FREE-RADICAL CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 1983-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TLR3, TLR9, TLR6 | CHRM1 4832/4885CHRM2 4805/4885CHRM4 4621/4885 |
| US-20250346553-A1 | Process for the Preparation of R-Oxybutynin Hydrochloride | GCG, GRHPR, CYP8B1 | CHRM1 581/4885CHRM2 577/4885CHRM4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.